If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TennesseeVanderbilt-Ingram Cancer Center, Nashville, Tennessee
Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TennesseeVanderbilt-Ingram Cancer Center, Nashville, Tennessee
Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TennesseeVanderbilt-Ingram Cancer Center, Nashville, Tennessee
Despite initial effectiveness of ALK receptor tyrosine kinase inhibitors (TKIs) in patients with ALK+ NSCLC, therapeutic resistance will ultimately develop. Serial tracking of genetic alterations detected in circulating tumor DNA (ctDNA) can be an informative strategy to identify response and resistance. This study evaluated the utility of analyzing ctDNA as a function of response to ensartinib, a potent second-generation ALK TKI.
Methods
Pre-treatment plasma was collected from 76 patients with ALK+ NSCLC who were ALK TKI–naive or had received prior ALK TKI, and analyzed for specific genetic alterations. Longitudinal plasma samples were analyzed from a subset (n = 11) of patients. Analysis of pre-treatment tumor biopsy specimens from 22 patients was compared with plasma.
Results
Disease-associated genetic alterations were detected in 74% (56 of 76) of patients, the most common being EML4-ALK. Concordance of ALK fusion between plasma and tissue was 91% (20 of 22 blood and tissue samples). Twenty-four ALK kinase domain mutations were detected in 15 patients, all had previously received an ALK TKI; G1269A was the most prevalent (4 of 24). Patients with a detectable EML4-ALK variant 1 (V1) fusion had improved response (9 of 17 patients; 53%) to ensartinib compared to patients with EML4-ALK V3 fusion (one of seven patients; 14%). Serial changes in ALK alterations were observed during therapy.
Conclusions
Clinical utility of ctDNA was shown, both at pre-treatment by identifying a potential subgroup of ALK+ NSCLC patients who may derive more benefit from ensartinib and longitudinally by tracking resistance. Prospective application of this technology may translate to improved outcomes for NSCLC patients treated with ALK TKIs.
You can add anaplastic lymphoma kinase here if you need the full name first.
ALK receptor tyrosine kinase (ALK) are detected in 3% to 8% of NSCLCs, and testing for ALK rearrangements is considered standard clinical practice for patients with metastatic disease.
Successful clinical trials have led to U.S. Food and Drug Administration approval of multiple ALK tyrosine kinase inhibitors (TKIs) in both the first-line and later lines of therapy.
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non–small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Lorlatinib in non–small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial.
Despite achieving initial responses, patients eventually progress, typically within 1 to 2 years. Mechanisms of acquired resistance to ALK TKIs include both on-target genomic alterations, that is, mutations in the ALK tyrosine kinase domain (KD) and amplification of the ALK fusion, as well as activation of bypass signaling networks.
Thus, accurate identification of tumor molecular evolution during therapy could have significant impact on the selection of therapy likely to have the greatest impact on patient outcomes.
The gold standard for detecting specific tumor mutations is analyzing tumor tissue, yet the lack of sufficient tissue available from certain biopsy procedures (e.g., fine needle aspirations) and the threat of complications arising from tissue biopsy procedures remain obstacles for obtaining genetic testing in some cases.
As a result, “liquid biopsies” that noninvasively quantify the molecular profile of tumors from circulating-tumor DNA (ctDNA) are an area of growing interest.
Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA.
A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR-mutant non–small cell lung cancer patients treated with erlotinib on a phase II trial.
Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non–small cell lung cancer by capture-based next-generation sequencing.
The question remains, however, whether analyzing ctDNA represents an adequate surrogate to tissue biopsy specimens and a feasible way to monitor disease response and resistance, especially within the scope of identifying ALK fusions and development of resistance mechanisms during ALK TKI therapy.
In this study, plasma was collected from ALK+ NSCLC patients who were enrolled on the phase I/II eXalt2 trial investigating safety and efficacy of ensartinib, a second-generation ALK inhibitor.
Additionally, ensartinib had good clinical activity in patients who were ALK TKI–naive or those who had received prior crizotinib, as well as in patients with lesions in central nervous system. Results from the phase I/II study formed the basis for the ongoing eXalt3 study (NCT02767804) comparing ensartinib to crizotinib in first-line therapy. The purpose of the current study was to evaluate the feasibility of ctDNA next-generation sequencing (NGS) to identify actionable genomic alterations, as well as monitor response and development of resistance to ensartinib. Additionally, we analyzed the concordance between ctDNA and paired tumor tissue, as well as the association of total detected ctDNA with progression-free survival (PFS).
Material and Methods
Serial plasma samples were collected from 76 patients with ALK+ NSCLC who were enrolled on the phase I/II multicohort eXalt2 trial (NCT01625234).
Cohorts included patients who: (1) were ALK TKI–naive, (2) received prior crizotinib only, and (3) received crizotinib and at least one second-generation ALK TKI. Archival tumor tissue was analyzed in a subset of patients (n = 25), as tissue collection was not mandated for patients enrolled on the study. This study was approved by the review boards at all participating institutions, and all patients provided written informed consent. The study was conducted in accordance with good clinical practice and the Declaration of Helsinki and its amendments.
Targeted NGS Analysis
Materials and methods describing the isolation of DNA from plasma and tissue are included in the Supplementary Methods. Analysis of tumor mutations using the Resolution Bioscience targeted hybrid-capture system has been described previously.
Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients.
Briefly, tissue and plasma samples collected at the time of enrollment (baseline) were hybridized to a panel of probes targeting single nucleotide variants (SNVs) and insertions and deletions (indels) in ALK, BRAF, EGFR, KRAS, MAP2K1, MET, NRAS, NTRK1, PIK3CA, RET, ROS1, and TP53. Specifically for ALK, the assay covers fusions in intron 19 and SNVs and indels in exons 20 through 29. This panel also targets gene fusion regions within ALK, RET, ROS1, and NTRK1, and contains additional probes for enhanced detection of copy variation in MET, as well as control probes on each autosome. After analysis of the corresponding tissue and the initial plasma time point, longitudinal plasma samples were analyzed with a reduced panel targeting ALK and TP53 only. Additional details can be found in the online supplement.
Statistical Analysis
The concordance between genetic alterations detected in the plasma and tissue was calculated in the subset of patients who had matched plasma and tissue samples at baseline. The Kaplan-Meier method was used to estimate PFS, and a Log-rank test was used to evaluate difference between groups. A Cox proportional hazards model was used to assess the association between PFS and ctDNA levels at baseline, which were measured as genomic equivalents (GEs) in the plasma. A Wilcoxon rank sum test was used to compare the GEs between responders and nonresponders; responders included any patient who experienced at least a partial tumor response to ensartinib. Two-sided p < 0.05 was considered statistically significant. As the eXalt2 trial was still ongoing at the time this manuscript was prepared, the data cutoff for all analyses was April 1, 2018.
In Vitro ALK Inhibitor Sensitivity
Methods for the in vitro ALK sensitivity experiments are presented in the Supplementary Methods. Primers for site-directed mutagenesis and Sanger sequencing are presented in Supplementary Tables 1 and 2, respectively.
Results
Patient Characteristics
We collected and analyzed baseline plasma samples from 76 patients with ALK+ NSCLC (Table 1, Supplementary Fig. 1). Pre-ensartinib plasma samples analyzed on cycle 1 day 1 were either from pooled pharmacokinetic samples (Supplementary Table 3) (n = 60, pre-dose and 2 to 3 hours post-dose) or one biomarker sample collected pre-dose (n = 16). We also collected and analyzed longitudinal samples from 11 patients who were selected based on availability of samples, response to ensartinib, and/or the presence of pre-treatment genetic alterations of interest. The median age was 56 years and 53% of patients were female. Of the entire cohort, 22% (17 of 76 patients) were ALK TKI–naive, 49% (37 of 76 patients) had received prior crizotinib, 20% (15 of 76 patients) had received prior crizotinib plus one second-generation ALK TKI (ceritinib or alectinib), and 9% (7 of 76 patients) had received prior crizotinib plus two second-generation ALK TKIs (ceritinib and either alectinib or brigatinib).
Table 1Patient Baseline Characteristics
Characteristics
Patients (%)
N = 76
Sex
Male
36 (47)
Female
40 (53)
Age, years
Median
56
Range
22-82
Race
White
58 (76)
Black/African American
2 (2)
Asian
12 (16)
Other/unknown
4 (5)
Smoking history
Current
3 (4)
Former
26 (34)
Never
47 (62)
No. of prior treatments
0
14 (18)
1
17 (22)
2
18 (24)
3
10 (13)
≥ 4
17 (22)
Prior ALK TKI treatment
ALK TKI naive
17 (22)
Prior crizotinib only
37 (49)
Prior crizotinib and ceritinib
9 (12)
Prior crizotinib and alectinib
6 (8)
Prior crizotinib, ceritinib, and alectinib
6 (8)
Prior crizotinib, ceritinib, and brigatinib
1 (1)
Values shown are n (%) unless otherwise stated. ALK, ALK tyrosine kinase; TKI, tyrosine kinase inhibitor
Detection of Disease-Associated Variants in Baseline Plasma Samples
In total, we detected disease-associated genomic alterations in the ctDNA of 56 (74%) of 76 patients (Fig. 1A), including SNVs, indels, and fusions, with ALK fusions being the most common alteration detected (50 of 76 patients, 66%). Sufficient input cell-free DNA was obtained and sequenced but no somatic variants were detected for 20 patients. Individual patient information regarding ALK fusion (variant and breakpoints), ALK KD mutations, and details of prior ALK TKIs and response to ensartinib are listed in Supplementary Tables 4 and 5. An EML4-ALK fusion was detected in 45 patients, with a range of variants (Fig. 1B). A PRKAR1A-ALK fusion was detected in one patient, which was confirmed via tissue NGS. Another patient had an AKAP8L-ALK fusion. Three other patients had a noncoding ALK rearrangement that could not be mapped to a specific fusion partner, but each patient responded to ensartinib (Supplementary Table 4).
Figure 1Detection of molecular alterations in plasma from patients with ALK+ NSCLC enrolled in the eXalt2 trial. A, Summary of all mutations identified by individual patient at the beginning of treatment with ensartinib. Alterations are color-coded per the figure legend below the image. The red or brown line around a particular mutation (or lack thereof) means that the mutation is either confirmed or not confirmed in the tissue, respectively. The mutation frequencies for each gene are graphed in the right panel, with the denominator equal to total number of patients (i.e., 76). Boxes with yellow and green alternating strips represent a gene for which both an SNV (yellow) and an indel (green) were detected. KRAS, NRAS, NTRK1, RET, and ROS1 were included in the NGS panel; however, no alterations in these genes were detected. B, Frequency of various ALK fusions detected in the plasma at the time of study entrance. “EML4-ALK Other” includes three patients with EML4-ALK fusions who had breakpoints in regions that could not be mapped to a specific variant. An ALK fusion of any kind was not detected in six patients. Frequencies in the bar graphs are expressed based upon the total number of patients (n = 76). C, Frequency and distribution of ALK kinase domain mutations detected across the study population. Orange bars represent samples from patients who had received prior crizotinib. Blue bars represent samples from patients who had received crizotinib and at least one second-generation ALK inhibitor. Frequencies are expressed based upon the total number of patients that received post-crizotinib (n = 37) or received post-crizotinib and a second-generation ALK inhibitor (n = 23). ALK, anaplastic lymphoma kinase gene; MET, mesenchymal-epithelial transition gene; MAP2K, mitogen-activated protein kinase 2 gene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; TP53, tumor protein p53 gene; MET, mesenchymal-epithelial transition gene; MAP2K, mitogen-activated protein kinase 2 gene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; TP53, tumor protein p53 gene; SNV, single nucleotide variant; CNV, copy number variant; NGS, next-generation sequencing.
Twenty-four ALK KD mutations were observed in 15 patients, with the most prevalent being G1269A (Fig. 1C). Overall mutation frequency in patients who received prior crizotinib as their only prior ALK TKI was 24% (9 of 37 patients). In the patients who received crizotinib and at least one second-generation ALK TKI, ALK KD mutations were detected in 27% (6 of 22 patients). ALK fusions were not identified in ctDNA of two patients with a secondary ALK mutation detected in the plasma, despite tumor samples from these patients being positive for an ALK rearrangement by fluorescence in situ hybridization; one patient was previously treated with crizotinib and the other received crizotinib followed by alectinib. We also detected alterations in five other genes (TP53, BRAF, MET, MAP2K1, and PIK3CA) within our patient population (Supplementary Table 6). Most notably, TP53 mutations were detected in plasma from 27 of 76 patients (35%). Additionally, a copy number variant in MET was detected in two patients. KRAS, NRAS, NTRK1, RET, and ROS1 were included in the NGS panel; however, no alterations in these genes were detected.
Concordance Between Tissue and Plasma Genotypes
NGS was also performed on pre-ensartinib tumor tissue in 25 patients; however, NGS analysis of tumor tissue from three patients failed due to insufficient tissue. Tumor and blood NGS testing results for detection of an ALK fusion matched in 20 of 22 patients (91%); 15 of 20 patients were fusion-positive, and 5 of 20 patients were fusion-negative. The patient with the PRKAR1A-ALK fusion in ctDNA was confirmed in the tissue; this patient also had a TP53 SNV that was confirmed in tissue. One of the five fusion negative patients had one non-ALK mutation (patient #63, TP53) detected in tissue and plasma; notably, this patient was ALK TKI–naive and subsequently progressed on ensartinib at the first imaging time point (i.e., 8 weeks), suggesting a false-positive ALK fluorescence in situ hybridization result. The other four fusion-negative (in both ctDNA and tissue NGS) patients did not have any disease-associated genetic alterations detected in the plasma (patients #16, #29, #54, and #55); however, all four patients experienced a partial response (PR) to ensartinib. Two of these four patients were ALK TKI–naive (patients #16 and #55), whereas the other two (patients #29 and #54) had previously received crizotinib as their only ALK TKI. All eight patients with TP53 mutations detected in pre-treatment tissue had the same mutation detected in ctDNA.
Of the 22 patients with tissue NGS, 4 patients had ALK KD mutations detected in plasma that were not detected in the tissue. One patient (patient #25, post crizotinib) had a G1269A mutation (allelic frequency [AF]: 0.1%) detected in the plasma, whereas an L1196M mutation (AF: 0.04%) mutation was detected in tissue (Supplementary Table 4); this patient showed a PR to ensartinib that lasted for 6 months. Another patient (patient #66, post crizotinib and ceritinib) who experienced a PR to ensartinib lasting 4 months had a G1202R mutation detected only in ctDNA (Supplementary Table 4). One patient who received prior crizotinib and ceritinib had D1203N (AF: 0.81%) and C1156Y (AF: 0.47%) mutations detected in plasma but not in tumor; this patient progressed on ensartinib at the first imaging time point (patient #31, Supplementary Table 4). S1206F (AF: 0.28%) was detected in the plasma of the fourth patient following crizotinib; however, a TP53 and mutation detected in ctDNA were detected in both plasma and tissue (patient #26, Supplementary Table 6). Collectively, these data suggest the notion that single-site biopsy specimens may not fully capture the spatial heterogeneity of mutations that might exist in subclones of tumors.
Correlation Between Baseline ctDNA Findings and Response to Ensartinib
As previous retrospective studies have shown differences in sensitivity to ALK TKIs according to EML4-ALK fusion variant (as defined by different genomic breakpoints within EML4),
we also examined the relationship between the detected variant in ctDNA and clinical response to ensartinib. Within our cohort, 39 patients had an EML4-ALK fusion detected in plasma and were efficacy-evaluable, which, similar to the parent clinical study, is defined as patients who received an effective dose of ensartinib (doses ≥200 mg) and had at least one post-baseline imaging assessment.
EML4-ALK variant 1 (V1) was detected in 17 of 39 (44%) patients, EML4-ALK variant 3 (V3) was detected in 7 of 39 (18%) patients, and other EML4-ALK variants (i.e., non-V1, non-V3) were detected in 12 of 39 (31%) patients (Fig. 1B; Supplementary Tables 4-5). The response rate (RR) in the efficacy-evaluable subcohort with an EML4-ALK V1 fusion was 53% (9 of 17 patients). However, the RR was only 14% (one of seven patients) in patients with a V3 fusion, despite one V3 fusion patient being on study longer than 12 months with stable disease. In patients who had received crizotinib as their only prior ALK TKI, RR was 78% (seven of nine patients) and 25% (one of four patients) for V1 and V3 fusion cohorts, respectively. Pooled objective response rate for patients with other EML4-ALK variants was 58% (7 of 12 patients); RR for those patients who had received crizotinib as their only prior ALK TKI was 67% (two of three patients). Excluding those ALK TKI–naive patients, the RRs for the V1 and V2/V5 fusion cohorts were 53% (8 of 15 patients) and 38% (three of eight patients), respectively. In this study, the EML4-ALK V3 fusion was not detected in any of the ALK TKI–naive patients.
PFS curves for patients with EML4-ALK fusion variants detected in the plasma at baseline are presented in Supplementary Figure 2. Within the efficacy-evaluable cohort, median PFS of patients exhibiting V1 and V3 fusion variants was 8.2 months (95% confidence interval [CI]: 2.1–11.7) and 1.9 months (95% CI: 1.8–not estimable), respectively. Pooled median PFS for patients with V2 or V5 fusion variants was 5.5 months (95% CI: 1.7–23.8). In patients who had received crizotinib as their only prior ALK TKI, the median PFS for the V1 and V3 cohorts was 10.9 months (95% CI: 5.4–16.4) and 2.2 months (95% CI: 1.8–not estimable), respectively. Excluding ALK TKI–naive patients, the median PFS for the V1 and V2/V5 cohorts was 7.4 months (95% CI: 1.8–11.6) and 4.4 months (95% CI: 1.5–not estimable), respectively.
Next, we evaluated whether clinical outcomes stratified with amount of ctDNA detected in baseline plasma samples. A Cox regression analysis showed that for every 1000-unit increase in GEs detected at baseline, the risk of disease progression significantly increased by 11% (hazard ratio: 1.11, 95% CI: 1.03–1.19). Additionally, a Wilcoxon rank sum test showed that the total plasma GEs in the patients who responded to ensartinib was significantly lower at baseline (p = 0.02) (Supplementary Fig. 3).
Lastly, we questioned whether baseline mutations in genes other than ALK portended response to ensartinib (Supplementary Table 6). Patients with a TP53 mutation at the start of the trial experienced significantly shorter median PFS compared with patients without TP53 mutation (3.7 months versus 11.6 months, respectively; p = 0.006). MET amplifications were observed in plasma from two patients before ensartinib therapy (patients #19 and #28) (Fig. 1A). MET amplification has previously been demonstrated as a mechanism of resistance to second generation ALK TKIs, such as alectinib.
One of these patients was unevaluable for response and the other had progressive disease as best response to ensartinib, suggestive of primary resistance to ensartinib therapy. Plasma from this patient did not reveal the presence of any ALK alteration.
Evolution of Response and Resistance During Molecular Surveillance
We sought to understand the activity of ensartinib in patients with baseline ALK KD mutations. Fifteen patients had at least one baseline ALK mutation (Supplemental Table 4); 9 of 12 efficacy-evaluable patients had stable disease or PR to ensartinib. Activity was seen in patients whose plasma harbored T1151M, L1152V, F1174V, L1196M, and G1269A; variable activity was observed between two patients who harbored a G1202R mutation (Supplementary Table 4). The difference in sensitivity to ensartinib between these two patients is thought to be influenced by the different AFs detected; the patient with a PR exhibited a G1202 mutation at an AF of 0.7%, whereas the mutation was detected at an AF of 2.1% for the patient with a progressive disease. Furthermore, as stated above, the G1202R mutation was only detected in the plasma of the patient with the PR and not the tumor tissue, suggesting that this subclone represented a small portion of the tumor.
From our entire cohort, longitudinal plasma samples were analyzed from 11 patients (Supplemental Figs. 4-11). These cases were selected based on sample availability, the patient’s response to ensartinib, and/or the presence of interesting ALK fusions or mutations detected at baseline. For example, an ALK E1154K mutation was detected in the plasma from patient #34, who had received prior crizotinib (Fig. 2A). To the best of our knowledge, this mutation has not previously been reported in clinical samples. We verified in vitro that ALK E1154K is sensitive to ensartinib (Supplementary Fig. 12). In agreement with these findings, the E1154K mutation was undetectable after two cycles of ensartinib and did not reappear upon ensartinib progression.
Figure 2Longitudinal assessment of molecular alterations detected in plasma during ensartinib treatment. Graphs show the change in allelic fraction of ALK and TP53 alterations for patient #34 (A), patient #74 (B), and patient #39 (C) during treatment with ensartinib. The time of radiographic response and progression are annotated below the x axis. An x axis point with a missing marker designates that plasma was not analyzed at that time point. The duration of each treatment cycle is 28 days.
Next, we sought to understand the mutations that emerge upon ensartinib progression. Patient #74 received prior treatment with crizotinib and ceritinib before enrolling in the ensartinib trial. At baseline (before the start of ensartinib), ALK L1152V (AF: 1.9%) and G1269A (AF: 0.13%) mutations were present, both of which disappeared with ensartinib treatment. The patient experienced a PR on ensartinib. However, a new ALK mutation, E1210K, was present at the time of radiographic progression (Fig. 2B). Glutamic acid (E) 1210 maps to the ribose-binding pocket of the ALK tyrosine kinase domain and has been reported in patients with crizotinib and brigatinib resistance.
In vitro data (Fig. 3) corroborates E1210K as a potential ensartinib vulnerability. This mutation appeared in plasma before radiographic progression, suggesting the potential utility of ctDNA analysis in monitoring the emergence of putative resistance mechanisms.
Figure 3Efficacy of ensartinib against ALK kinase domain mutations. BA/F3 cells expressing the indicated ALK kinase domain mutations within the context of EML4-ALK variant 1 (A) or EML4-ALK variant 3 (B) were treated with increasing concentrations of crizotinib, ceritinib, ensartinib, alectinib, brigatinib, and lorlatinib (0-10 μmol/L) for 72 hours. Cell titer blue assays were performed to assess cell viability. Experiments were performed with six replicates per drug concentration and repeated three times. Concentration inhibiting 50% (IC50) values with 95% confidence intervals were generated with the data from the dose response curves using GraphPad Prism 7. All variants were tested three independent times, except for V1 E1210K, V3 D1203N, and V3 E1210K, which were tested two independent times. WT, wild type.
As an additional example, an EML4-ALK V5 fusion was detectable in both the plasma and tissue of the ALK TKI–naive patient #39 (Fig. 2C). As expected, no ALK KD mutations were detected at the start of the trial because the patient had not previously been exposed to an ALK TKI. This patient experienced a PR lasting 11 cycles, coinciding with a decrease in the EML4-ALK V5 AF. At the time of disease progression, the original EML4-ALK V5 fusion re-emerged in the plasma, and there was also emergence of an EML4-ALK V3 fusion and an ALK S1206F mutation at an AF of 5.2%. Ensartinib is active against S1206F mutation in vitro (concentration that inhibits 50% [IC50] < 50 nM for V1 and V3) (Fig. 3). It is unclear from this case whether S1206F mutation was truly driving ensartinib resistance, or if there were other genetic alterations present that were not evaluated on our panel. A new TP53 frameshift mutation was also detectable at progression, with six distinct TP53 variants found in the plasma from this patient. Overall, these results suggest underlying tumor heterogeneity within this individual patient.
Comparison of Patient ctDNA With In Vitro ALK Inhibitor Sensitivity Analysis
We examined the activity of crizotinib, ensartinib, and other second- and third-generation ALK TKIs (ceritinib, alectinib, brigatinib, and lorlatinib) against wild-type EML4-ALK V1 (E12;A20) and V3 (E6;A20), as well as both EML4-ALK fusions harboring various ALK mutations (Figs. 3A and B and Supplementary Fig. 13). Compared to the other ALK TKIs, ensartinib was the most potent inhibitor against G1123S and L1198F mutations; G1123S has previously been reported in a patient who exhibited resistance to ceritinib.
Our in vitro data would suggest that samples exhibiting either of these mutations would not be sensitive to ceritinib, but could potentially be sensitive to ensartinib (IC50 < 1 nM). Conversely, our in vitro data suggest that ensartinib would be less active against G1202R (IC50 = 316 nM) and G1269A (IC50 = 222 nM) mutations. In fact, one patient (patient #7) with a G1202R mutation at baseline did not respond to ensartinib. G1269A was present at baseline in another patient (Supplementary Fig. 6, patient #25) which fluctuated in plasma throughout ensartinib treatment, and then was again present at the time of radiographic progression. Additionally, one patient (Supplementary Fig. 10, patient #66) had a G1202R mutation at baseline that was not detected after starting ensartinib but was again present along with a G1269A mutation at progression. In vitro studies do not always predict results that will be observed clinically, which may explain why a few patients with G1202R or G1269A mutations responded to ensartinib. Although these patients responded, the response was not durable and these patients eventually developed disease progression on ensartinib.
Discussion
Personalized medicine offers the ability to tailor a patient’s cancer treatment based on a number of factors, including molecular status. This is especially true for patients with ALK+ NSCLC, where clinical outcome is significantly improved after treatment with an ALK TKI compared to traditional chemotherapy.
Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.
Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial.
Thus, tracking the evolution of resistance is imperative in this patient population. Serial tissue sampling remains the gold standard for quantifying the genomic landscape of tumors; however it often fails to capture the dynamic and heterogeneous nature of acquired resistance. Here, we present, as proof of concept, findings from the eXalt2 study that highlight the potential clinical utility of hybrid-capture NGS of ctDNA at predicting response and acquired resistance to the ALK TKI ensartinib. This is the first study to highlight treatment response and resistance mechanisms to ensartinib, both in vivo and in vitro.
In our cohort of 76 patients, genetic alterations were detected in 74% (56 of 76 patients) of plasma samples, which is similar to prior reports investigating the clinical utility of ctDNA.
Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non–small cell lung cancer by capture-based next-generation sequencing.
We observed plasma ALK mutations in 24% of patients who had prior crizotinib, and in 27% of patients receiving prior crizotinib and a second-generation ALK TKI (i.e., ceritinib or alectinib). These data are in accord with previous studies of crizotinib resistance; however, we detected a lower frequency of ALK KD mutations post second-generation ALK TKIs (ceritinib and alectinib) than previously reported in tissue biopsy specimens obtained by Gainor et al.
This may be a sampling issue, as only 22 of 76 patients in this study had received a prior second-generation ALK TKI, or could be an artifact of the original study design that did not include standard collection and processing protocols for all plasma samples. However, of the 13 patients who did not have an ALK mutation detected in the plasma, 12 had an ALK fusion detected and the other patient had non-ALK mutations (TP53 and MAP2K1) detected, suggesting that these plasma samples contained sufficient ctDNA for analysis.
Overall, there was a high degree (91%) of fusion concordance between plasma and tissue NGS analyses, which is similar to the previous study by Dagogo-Jack et al.
that reported a fusion concordance of 86% between plasma and tissue. Tissue sequencing failed to detect ALK genetic alterations detected in the plasma of four patients, thereby providing supporting evidence that tissue sampling may not always fully capture the genetic heterogeneity of tumors.
In our cohort, 35% (27 of 76) of patients had TP53 mutations detected in the plasma at baseline. Similar percentage (36%) was observed in patients who had received at least one prior ALK TKI. Specifically in the cohort of patients who had prior crizotinib and at least one second-generation ALK TKI, 50% (11 of 22) of patients had TP53 mutations detected in the plasma at baseline. Our results were slightly higher than two previous studies by Gainor et al.
who reported 36% (9 of 25 patients, post ceritinib or alectinib) and 41% (36 of 88 patients, prior ALK status could not be confirmed) of patients exhibited a TP53 mutation in their tumor or plasma, respectively.
Objective response rate and PFS were improved, albeit not significantly, in patients with an EML4-ALK V1 fusion compared to those with a V3 fusion. Even the pooled clinical outcome data with patients exhibiting either a V2 or V5 fusion variant was better than the V3 patients; however, these results were also not statistically different. The lack of statistical significance could be due to the small numbers of patients in each of these categories. Nonetheless, these results collectively suggest that ensartinib is more active against the EML4-ALK V1 variant, and the differential improvement in antitumor activity does not appear to depend on prior treatment with ALK TKIs. These results are especially important given the emerging studies that have reported differential sensitivities to ALK TKIs according to ALK variant.
Prospective use of ctDNA analysis, specifically quantifying the ALK fusion variant, would be useful, for example, when defining eligibility criteria for future clinical trials evaluating ensartinib, as well as other ALK TKIs.
In addition to providing potential prognostic information at baseline, serial analysis of ctDNA could provide information regarding specific genetic determinants of acquired resistance. Although this study was limited by the small number of patients with longitudinal ctDNA analysis, we show that serial changes in ALK mutation AFs were detected while on treatment with ensartinib, demonstrating that analyzing ctDNA has the potential to track tumor response and the evolution of acquired resistance. We are not the first group to serially quantify ctDNA as a function of ALK TKI therapy. Dagogo-Jack et al.
analyzed plasma ALK mutation kinetics during treatment and observed decreases in AFs of the ALK fusion and KD mutation with response to the ALK TKI, and then resurgence of the same genetic alteration at the time of disease progression. Wang et al.
Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non–small cell lung cancer by capture-based next-generation sequencing.
analyzed longitudinal blood samples from seven patients undergoing crizotinib and observed similar trends in the mutant AF of ALK and ctDNA concentration. Unique to our study, however, is the analysis of plasma samples collected during ensartinib where the resurgence or development of new genetic alterations that are driving tumor resistance could be detected before radiographic progression. Collectively, results from these studies suggest that serial monitoring of genetic biomarkers that are associated with acquired resistance is feasible. Application of this technology would allow for a physician to change therapy before progression, thereby reducing the time a patient receives an ineffective therapy and potentially improving clinical outcome by switching to another, more effective treatment. However, validation of such an approach would require evaluation in a prospective clinical trial. Additionally, the targeted NGS analysis performed on the longitudinal samples in this study only included two genes, thus limiting the number of potential mechanisms of resistance that could be detected; future studies will include a more comprehensive targeted NGS panel.
In conclusion, clinical utility of ctDNA was shown in this study, both at pre-treatment by demonstrating a potential subgroup of ALK+ NSCLC patients who may derive more clinical benefit from ensartinib, and serially tracking genetic determinants of resistance. Prospective application of this technology could translate to improved outcomes for NSCLC patients treated with ALK TKIs.
Acknowledgments
This work was supported by Xcovery Holdings and Resolution Biosciences. Work in the CML laboratory is supported through the National Institutes of Health (NIH) and National Cancer Institute (NCI) R01CA121210 and P01CA129243, the Damon Runyon Foundation, the LUNGevity Foundation, the V Foundation, the Lung Cancer Foundation of America, and the International Association for the Study of Lung Cancer. CML was also supported through P30CA6848. The authors thank the patients and their families for participating in this study; Yingjun Yan for her technical assistance; and Merrida Childress, PhD, for thoughtful discussion regarding the interpretation of results.
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non–small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Lorlatinib in non–small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial.
Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA.
A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR-mutant non–small cell lung cancer patients treated with erlotinib on a phase II trial.
Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non–small cell lung cancer by capture-based next-generation sequencing.
Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients.
Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.
Disclosure: Dr. Horn has received personal fees from AbbVie, AstraZeneca, Bristol-Myers Squibb, Lilly, Incyte, EMD Serono, Merck, Roche-Genentech, Tessaro, and Xcovery; and reports receiving commercial research support from Boehringer Ingelheim. Dr. Whisenant has received personal fees from Anasys Instruments. Dr. Wakelee is a consultant/advisory board member for AstraZeneca, Genentech/Roche (uncompensated), Merck (uncompensated), Novartis (uncompensated), and Ariad (uncompensated); and has received grants to her institution for conduct of clinical trial work from Genentech/Roche, Novartis, Pfizer, Lilly, Celgene, AstraZeneca/Medimmune, Exelixis, Clovis Oncology, Bristol-Myers Squibb, Gilead, Pharmacyclics, ACEA Biosciences, Merck, and Xcovery. Dr. Reckamp is a consultant/advisory board member for ARIAD Takeda, Exelixis, Guardant, Loxo, and Genentech; and has received grants from Xcovery, AbbVie, Acea, Adaptimmune, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Guardant, Janssen, Loxo Oncology, Seattle Genetics, Takeda, and Zeno. Dr. Leal is a consultant/advisory board member for Roche-Genentech, Ariad, Takeda, AstraZeneca, Novartis, AbbVie, and Bristol-Myers Squibb. Dr. Blumenschein has served as a consultant for Abbvie, Adicet, Amgen, ARIAD, Bayer, Bristol-Myers Squibb, Celgene, Clovis, Merck, Novartis, and Xcovery; and has received research funding from Adaptimmune, Bayer, Bristol-Myers Squibb, Celgene, Exelixis, Genetech, GlaxoSmithKline, Hoffman-La Roche, Immatics, Incyte, Macrogenetics, MedImmune, Merck, Novartis, Torque, and Xcovery. Dr. Waqar has received the 1 UM1 CA186704-01 grant; and as institutional PI has received support from F. Hoffmann-La Roche, Ltd., Ariad, Pfizer Pharmaceuticals, Inc., Hengrui Therapeutics, Xcovery, EMD Serono Research and Development Institute, Inc., Checkpoint Therapeutics, Inc., Genentech, Inc., Lilly, Stemcentrx, Inc., Ignyta, Inc., Bristol-Myers Squibb Pharmaceutical, Synemore Biologics Co., Ltd., Novartis Pharmaceuticals Corporation, Merck & Company, Inc., NewLink Genetics Corporation, and Celgene. Dr. Patel is a scientific advisory board member for AstraZeneca, Bristol-Myers Squibb, Illumina, Tempus, and Novartis; and has received research funding from Bristol-Myers Squibb, Eli Lilly, Fate, Incyte, AstraZeneca/MedImmune, Merck, Pfizer, Roche/Genentech, Xcovery, Fate Therapeutics, Genocea, and Iovance. Research funds were distributed through University of California San Diego. Dr. Nieva has received personal fees from Roche and Takeda. Dr. Oxnard is a consultant for Takeda, AstraZeneca, Loxo, Inivata, and GRAIL. Dr. Sanborn is a consultant/advisory board member for ARIAD and Takeda. Drs. Hernandez, Shaffer, Garg, Lim, and Li are employees and shareholders of Resolution Biosciences. Dr. Holzhausen is an employee of Xcovery Holdings, Inc. Drs. Harrow and Liang are employees of and have ownership interests (including patents) in Xcovery Holdings, Inc. Dr. Lovly has served as a consultant for Pfizer, Novartis, Astra Zeneca, Genoptix, Sequenom, Ariad, Takeda, Foundation Medicine, Blueprints Medicine, and Cepheid; and has received research funding from Novartis, AstraZeneca, and Xcovery (the funds were distributed through Vanderbilt University, not given to Dr. Lovly directly). The remaining authors declare no conflict of interest.
30665-3&id=gr1.jpg){kind=link}
30665-3&id=gr2.jpg){kind=link}
30665-3&id=gr3.jpg){kind=link}